UBX
Price:
$1.26
Market Cap:
$21.23M
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed ...[Read more]
Industry
Biotechnology
IPO Date
2018-05-03
Stock Exchange
NASDAQ
Ticker
UBX
According to Unity Biotechnology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.66. This represents a change of -42.43% compared to the average of -1.15 of the last 4 quarters.
The mean historical PE Ratio of Unity Biotechnology, Inc. over the last ten years is -2.35. The current -0.66 PE Ratio has changed 2.71% with respect to the historical average. Over the past ten years (40 quarters), UBX's PE Ratio was at its highest in in the March 2023 quarter at -0.48. The PE Ratio was at its lowest in in the December 2017 quarter at -13.91.
Average
-2.35
Median
-1.62
Minimum
-6.02
Maximum
-0.45
Discovering the peaks and valleys of Unity Biotechnology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 369.47%
Maximum Annual PE Ratio = -0.45
Minimum Annual Increase = -66.81%
Minimum Annual PE Ratio = -6.02
Year | PE Ratio | Change |
---|---|---|
2023 | -0.72 | 58.78% |
2022 | -0.45 | -66.81% |
2021 | -1.36 | -53.22% |
2020 | -2.90 | -30.94% |
2019 | -4.20 | -30.18% |
2018 | -6.02 | 369.47% |
2017 | -1.28 | -31.92% |
The current PE Ratio of Unity Biotechnology, Inc. (UBX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.84
5-year avg
-1.93
10-year avg
-2.35
Unity Biotechnology, Inc.’s PE Ratio is greater than Exscientia plc (-3.77), greater than Recursion Pharmaceuticals, Inc. (-4.29), greater than Atea Pharmaceuticals, Inc. (-1.60), greater than Icosavax, Inc. (-8.27), greater than HOOKIPA Pharma Inc. (-0.97), greater than Acumen Pharmaceuticals, Inc. (-2.73), greater than Heron Therapeutics, Inc. (-5.63), less than Homology Medicines, Inc. (-0.01), greater than Avidity Biosciences, Inc. (-18.98), greater than Beam Therapeutics Inc. (-14.02), greater than Intellia Therapeutics, Inc. (-2.89), greater than Editas Medicine, Inc. (-1.23), greater than Verve Therapeutics, Inc. (-2.65), greater than Prime Medicine, Inc. (-2.17), less than Windtree Therapeutics, Inc. (-0.04), less than Dermata Therapeutics, Inc. (-0.08), less than Ensysce Biosciences, Inc. (-0.45), less than Panbela Therapeutics, Inc. (-0.06), less than Baudax Bio, Inc. (-0.21), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Nuvation Bio Inc. (-1.10), greater than Ovid Therapeutics Inc. (-2.81), less than NextCure, Inc. (-0.60), less than Connect Biopharma Holdings Limited (8.69),
Company | PE Ratio | Market cap |
---|---|---|
-3.77 | $636.36M | |
-4.29 | $1.89B | |
-1.60 | $282.81M | |
-8.27 | $769.04M | |
-0.97 | $45.33M | |
-2.73 | $177.24M | |
-5.63 | $269.97M | |
-0.01 | $3.02M | |
-18.98 | $5.25B | |
-14.02 | $2.01B | |
-2.89 | $1.54B | |
-1.23 | $237.53M | |
-2.65 | $511.98M | |
-2.17 | $475.32M | |
-0.04 | $6.12M | |
-0.08 | $1.84M | |
-0.45 | $8.63M | |
-0.06 | $1.80M | |
-0.21 | $8.13M | |
-0.98 | $8.20M | |
-1.10 | $764.36M | |
-2.81 | $83.75M | |
-0.60 | $36.65M | |
8.69 | $66.30M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Unity Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Unity Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Unity Biotechnology, Inc.'s PE Ratio?
How is the PE Ratio calculated for Unity Biotechnology, Inc. (UBX)?
What is the highest PE Ratio for Unity Biotechnology, Inc. (UBX)?
What is the 3-year average PE Ratio for Unity Biotechnology, Inc. (UBX)?
What is the 5-year average PE Ratio for Unity Biotechnology, Inc. (UBX)?
How does the current PE Ratio for Unity Biotechnology, Inc. (UBX) compare to its historical average?